Lead Product(s) : Leronlimab
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Marketed as Vyrologix, leronlimab is an investigational humanised immunoglobulin G4 monoclonal antibody that hinders C-C chemokine receptor type 5 (CCR5).
Product Name : Vyrologix
Product Type : Antibody
Upfront Cash : Inapplicable
May 27, 2021
Lead Product(s) : Leronlimab
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Gam-COVID-Vac
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Brazilian Approval of Sputnik V Vaccine Delayed by Missing Data
Details : Documents supporting drugmaker Uniao Quimica’s application for emergency use of Sputnik V have been returned to the company because they did not meet its minimum criteria.
Product Name : Sputnik V
Product Type : Vaccine
Upfront Cash : Inapplicable
January 17, 2021
Lead Product(s) : Gam-COVID-Vac
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : VLA1553
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Valneva
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
December 02, 2020
Lead Product(s) : VLA1553
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Valneva
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Inactivated Vero Cell
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
China's Sinovac Vaccine is Safe, Brazil Institute Says
Details : São Paulo’s Butantan Institute, one of Brazil’s leading biomedical research centers, which is carrying out the Phase 3 tests, said the two-dose vaccine, called CoronaVac, proved to be safe in a trial so far involving 9,000 volunteers.
Product Name : CoronaVac
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
October 19, 2020
Lead Product(s) : Inactivated Vero Cell
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : COVID-19 Vaccine (Inactivated, Adsorbed)
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Sinovac Biotech
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
July 02, 2020
Lead Product(s) : COVID-19 Vaccine (Inactivated, Adsorbed)
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Sinovac Biotech
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ivermectin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Biorasi
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 09, 2017
Lead Product(s) : Ivermectin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Biorasi
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Irlanda-1-Association
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Efficacy and Safety of Irlanda-1-Association on the Treatment of Common Cold in Children
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
January 15, 2016
Lead Product(s) : Irlanda-1-Association
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Irlanda-2-Association
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Efficacy and Safety of Irlanda-2 Association on the Treatment of Common Cold
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
January 15, 2016
Lead Product(s) : Irlanda-2-Association
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Clotrimazole
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Effectiveness Study of Ketoconazole and Betamethasone to Treat Fungal Infection and Dermatophytosis
Details : Undisclosed
Product Name : Candicort
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 21, 2015
Lead Product(s) : Clotrimazole
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Naphazoline Hydrochloride
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 15, 2012
Lead Product(s) : Naphazoline Hydrochloride
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable